Cytokinetics (CYTK) Tops Q2 EPS by 13c
Tweet
Share
E-mail
Get Alerts CYTK Hot Sheet
Price: $72.72 -1.66%
Revenue Growth %: +1,960.6%
Financial Fact:
Research and development, grant and other revenues: 441K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +1,960.6%
Financial Fact:
Research and development, grant and other revenues: 441K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q2 EPS of ($1.50), $0.13 better than the analyst estimate of ($1.63). Revenue for the quarter came in at $28.6 million versus the consensus estimate of $17.09 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Concurrent Technologies (CNC:LN) PT Raised to GBP3.20 at Berenberg
- JPMorgan Downgrades Woolworths Holdings Ltd (WHL:SJ) to Underweight
- UBS Upgrades E.ON SE (EOAN:GR) (EONGY) to Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
